EG19814A - A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose - Google Patents

A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose

Info

Publication number
EG19814A
EG19814A EG41291A EG41291A EG19814A EG 19814 A EG19814 A EG 19814A EG 41291 A EG41291 A EG 41291A EG 41291 A EG41291 A EG 41291A EG 19814 A EG19814 A EG 19814A
Authority
EG
Egypt
Prior art keywords
flupirtine
thr
agent
preparation
active substance
Prior art date
Application number
EG41291A
Other languages
English (en)
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Application granted granted Critical
Publication of EG19814A publication Critical patent/EG19814A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrrole Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Paints Or Removers (AREA)
  • Golf Clubs (AREA)
  • Details Of Television Scanning (AREA)
  • Medicines Containing Plant Substances (AREA)
EG41291A 1990-07-14 1991-07-09 A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose EG19814A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4022442 1990-07-14
IN421CA1991 IN172468B (fr) 1990-07-14 1991-06-04

Publications (1)

Publication Number Publication Date
EG19814A true EG19814A (en) 1996-02-29

Family

ID=25895002

Family Applications (1)

Application Number Title Priority Date Filing Date
EG41291A EG19814A (en) 1990-07-14 1991-07-09 A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose

Country Status (30)

Country Link
US (2) US5162346A (fr)
EP (2) EP0467164B1 (fr)
KR (1) KR0182811B1 (fr)
CN (1) CN1070700C (fr)
AT (2) ATE206919T1 (fr)
AU (1) AU634073B2 (fr)
CA (1) CA2046943C (fr)
CZ (1) CZ280879B6 (fr)
DE (3) DE59109222D1 (fr)
DK (2) DK0659410T3 (fr)
EG (1) EG19814A (fr)
ES (2) ES2082887T3 (fr)
GR (1) GR3019179T3 (fr)
HR (1) HRP920667B1 (fr)
HU (1) HU206973B (fr)
IE (1) IE74688B1 (fr)
IL (1) IL98810A (fr)
IN (1) IN172468B (fr)
LT (1) LT3593B (fr)
LV (1) LV10048B (fr)
MC (1) MC2272A1 (fr)
MX (1) MX9100160A (fr)
NO (1) NO912758L (fr)
NZ (1) NZ238940A (fr)
PT (1) PT98291B (fr)
RO (1) RO108220B1 (fr)
RU (1) RU2070408C1 (fr)
SI (1) SI9111227B (fr)
SK (1) SK279567B6 (fr)
ZA (1) ZA915466B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
DE4319649A1 (de) * 1993-03-18 1994-09-22 Asta Medica Ag Feste Flupirtin enthaltende orale Darreichungsformen mit kontrollierter Wirkstoffabgabe
DE4327516A1 (de) * 1993-08-17 1995-02-23 Asta Medica Ag Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin
GB9426079D0 (en) * 1994-12-23 1995-02-22 Orion Yhtymae Oy A gelatine capsule
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
US6284794B1 (en) 1996-11-05 2001-09-04 Head Explorer Aps Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase
US6610324B2 (en) * 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
CZ2002411A3 (cs) * 1999-08-03 2003-03-12 Awd. Pharma Gmbh & Co. Kg Farmaceutický prostředek pro léčení bolesti stejně jako prevenci chronických bolestí při degenerativních chorobách kloubů u psů a koček
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
RU2213565C1 (ru) * 2002-06-24 2003-10-10 Общество с ограниченной ответственностью "Паркинфарм" Способ лечебного воздействия на организм пациента при лечении болезни паркинсона
DE10255415A1 (de) * 2002-11-28 2004-06-09 Bayer Healthcare Ag Dermale Applikation von Flupirtin
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE102004001558A1 (de) * 2004-01-10 2005-08-18 Bayer Healthcare Ag Arzneimittel zur topischen Applikation bei Tieren
US20050196461A1 (en) * 2004-01-14 2005-09-08 Udell Ronald G. Ceramide formulations suitable for oral administration
WO2005072705A1 (fr) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combinaison d'antagoniste de recepteur nmda et d'inhibiteur mao ou gadpf pour le traitement d'affections liees au systeme nerveux central
US20050220862A1 (en) * 2004-03-31 2005-10-06 Bernstein Joel E Compositions with reduced hepatotoxicity
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
EP1688141A1 (fr) * 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
MX2007012374A (es) 2005-04-06 2008-02-22 Adamas Pharmaceuticals Inc Metodos y composiciones para el tratamiento de condiciones relacionadas con cns.
US20090318507A2 (en) * 2006-05-02 2009-12-24 Chris Rundfeldt Potassium Channel Activators for the Prevention and Treatment of Dystonia and Dystonia Like Symptoms
US7960436B2 (en) * 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
PT2061465E (pt) * 2006-08-23 2013-07-15 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil)anilidas como moduladores do canal de potássio
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8030518B2 (en) * 2006-11-28 2011-10-04 Valeant Pharmaceuticals International 1,4 diamino bicyclic retigabine analogues as potassium channel modulators
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
EA201070189A1 (ru) * 2007-08-01 2010-08-30 Х. Лундбекк А/С Применение соединений, открывающих калиевые каналы kcnq, для подавления симптомов или лечения расстройств или состояний, при которых нарушается дофаминергическая система
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
ES2347119B2 (es) * 2009-04-22 2011-04-28 Universidad De Santiago De Compostela Nanocapsulas de poliarginina.
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
JP6251667B2 (ja) * 2014-06-03 2017-12-20 アサヒカルピスウェルネス株式会社 錠剤型即放性製剤及びその製造方法
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1795858C2 (de) 1968-07-19 1979-01-11 Deutsche Gold- Und Silber-Scheideanstalt Vormals Roessler, 6000 Frankfurt Benzylaminopyridine
DE3133519A1 (de) 1980-09-13 1982-06-09 Degussa Ag, 6000 Frankfurt "2-amino-3-carbethoxyamino-6-(p-fluor-benzylamino)-pyridin-maleat"
ATE46265T1 (de) * 1985-01-23 1989-09-15 Asta Pharma Ag Synergistische kombination von flupirtin und nicht-steroidalen antiphlogistika.
EP0193056B1 (fr) * 1985-02-23 1989-06-07 ASTA Pharma Aktiengesellschaft Combinaison de la flupirtine avec des spasmolytiques à effet anticholinergique
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
FI855016A (fi) * 1985-06-28 1986-12-29 Degussa Synergistisk kombination av flupirtin och 4-acetamido-fenol.

Also Published As

Publication number Publication date
HUT59313A (en) 1992-05-28
NO912758D0 (no) 1991-07-12
DK0467164T3 (da) 1996-03-04
MX9100160A (es) 1992-02-28
PT98291A (pt) 1992-05-29
EP0467164A3 (en) 1992-04-15
CA2046943A1 (fr) 1992-01-15
ES2082887T3 (es) 1996-04-01
HRP920667B1 (en) 1998-06-30
PT98291B (pt) 1999-01-29
ATE133564T1 (de) 1996-02-15
IE74688B1 (en) 1997-07-30
LTIP919A (en) 1995-03-27
US5284861A (en) 1994-02-08
DK0659410T3 (da) 2001-12-27
DE59107331D1 (de) 1996-03-14
EP0467164A2 (fr) 1992-01-22
LV10048A (lv) 1994-05-10
EP0659410B1 (fr) 2001-10-17
CZ280879B6 (cs) 1996-04-17
AU634073B2 (en) 1993-02-11
SI9111227A (en) 1995-06-30
ZA915466B (en) 1992-04-29
MC2272A1 (fr) 1993-06-23
SK279567B6 (sk) 1999-01-11
RU2070408C1 (ru) 1996-12-20
EP0659410A3 (fr) 1995-10-25
KR920002147A (ko) 1992-02-28
IL98810A0 (en) 1992-07-15
LT3593B (en) 1995-12-27
LV10048B (en) 1995-06-20
HU206973B (en) 1993-03-01
CA2046943C (fr) 1996-03-12
IN172468B (fr) 1993-08-14
ES2164111T3 (es) 2002-02-16
CS210191A3 (en) 1992-02-19
KR0182811B1 (ko) 1999-05-01
RO108220B1 (ro) 1994-03-31
GR3019179T3 (en) 1996-06-30
CN1070700C (zh) 2001-09-12
IL98810A (en) 1996-01-19
IE912451A1 (en) 1992-01-15
HRP920667A2 (en) 1996-10-31
EP0467164B1 (fr) 1996-01-31
NZ238940A (en) 1997-05-26
US5162346A (en) 1992-11-10
CN1058716A (zh) 1992-02-19
HU912359D0 (en) 1991-12-30
SI9111227B (sl) 2000-12-31
ATE206919T1 (de) 2001-11-15
NO912758L (no) 1992-01-15
DE59109222D1 (de) 2001-11-22
AU8040391A (en) 1992-01-16
EP0659410A2 (fr) 1995-06-28
DE4122166A1 (de) 1992-01-16

Similar Documents

Publication Publication Date Title
EG19814A (en) A process for thr preparation of an agent with the active substance flupirtine to combat muscular tension and the use of flupirtine for such purpose
EP0460912A3 (en) Medicaments for the treatment of sexual disorder
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
ZA878652B (en) Agents for combating pests and plant treatment agents
EP0331620A3 (en) Agent for the treatment of parkinson's disease
EP0427026A3 (en) Compositions for treating fat deposits in humans
EP0279887A3 (en) Carnitine directed pharmaceutical agents and their use for the manufacture of a medicament for the treatment of muscle disorder
NZ227588A (en) Whey treatment, reduction of lipoprotein content
MY104521A (en) Treatment of depression.
PH27352A (en) 4-Benzyl-5-phenyl-2,4-dihydro-3h-1,2,4-triazol-3-ones and their use as anticonvulsants
NZ222045A (en) From diamides up to tetrapeptides for use as anticanvulsants
IL89082A0 (en) Compounds with a psychotropic action,agents containing them,and the use thereof for the treatment and prophylaxis of disorders of the central nervous system
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
EP0872246A4 (fr) Nouveau medicament pour attenuer la douleur et favoriser l'elimination des calculs lies a l'urolithiase
ZA913920B (en) Therapeutic compound
EP0436717A4 (en) Method of treatment with medical agents
GR3002925T3 (en) Compound active in cardiovascular therapy
EP0182569A3 (en) Use of 1,6-dimethyl-4-oxo-1,6,7,8,9a-hexahydro-4h-pyridoû1,2-a¨pyrimidine-3-carboxamide for the prevention and treatment of gastrointestinal damages
GEP19971009B (en) Flupirtine in combination with antiparkinsonica against muscle bracing
BG98001U (en) Medicament for the treatment of hyperkeratotic conditions of the skin
ZA923505B (en) Treatment of fatigue syndrome
ZA89574B (en) Compounds with a psychotropic action,agents containing them,and the use thereof for the treatment and prophylaxis of disorders of the central nervous system
IE900102L (en) Treatment of skin disorders